SMARCA4/BRG1缺陷型非小细胞肺癌的临床病理特点和治疗策略  

Clinicopathological features and treatment strategies of SMARCA4/BRG1-deficient non-small cell lung cancer

作　　者：陈沁阳 张杰[3] 谢晓慧 吴名娇 冯健伟 陈娟(综述) 姚文秀(审校) Qinyang Chen;Jie Zhang;Xiaohui Xie;Mingjiao Wu;Jianwei Feng;Juan Chen;Wenxiu Yao(Clinical College,Chengdu Medical College,Chengdu 610041,China;Department of Thoracic Oncology,Sichuan Cancer Institute,Sichuan Cancer Prevention and Control Center,Cancer Hospital Affiliated to School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Oncology,The First Affiliated Hospital of Chengdu Medical College,Chengdu 610500,China)

机构地区：[1]成都医学院临床医学院,成都市610500 [2]四川省肿瘤医院胸部肿瘤内科,四川省肿瘤研究所,四川省癌症防治中心,电子科技大学医学院附属肿瘤医院 [3]成都医学院第一附属医院肿瘤科

出　　处：《中国肿瘤临床》2022年第3期155-158,共4页Chinese Journal of Clinical Oncology

摘　　要：SWI/SNF复合体是一个含有10~15个亚基的多蛋白复合体,参与重要的细胞进程和功能调控,突变频率较高,最常见的突变亚基为SMARCA4/BRG1。SMARCA4/BRG1缺失的非小细胞肺癌(SMARCA4-deficient non-small lung cancer,SMARCA4-dNSCLC)具有恶性程度高、肿瘤发展迅速、生存率低等特点。SMARCA4-dNSCLC经常发生SMARCA4和KRAS、TP53、KEAP1、STK11共突变的情况,但ALK、EGFR、ROS1等常见突变几乎均为阴性,因此传统的肺癌治疗模式对SMARCA4-dNSCLC效果有限,新型治疗策略的出现或是解决问题的关键。本文将对SMARCA4-dNSCLC的临床病理特点和新型治疗策略进行综述。The SWI/SNF complex is a multiprotein complex with 10–15 subunits,and it is involved in regulating important cellular processes and functions.It is also frequently mutated,with the most commonly mutated subunit being SMARCA4/BRG1.SMARCA4/BRG1-deficient non-small cell lung cancer(SMARCA4-dNSCLC)is characterized by highly malignant,rapid tumor progression and low survival rates.SMARCA4-dNSCLC often features co-mutations of SMARCA4 and KRAS,TP53,KEAP1,and STK11,but tests for almost all common mutations such as ALK,EGFR,and ROS1 are negative.Thus,traditional treatments may have limited efficacy and new treatment strategies are required.This review summarizes the clinicopathological features of and novel treatment strategies for SMARCA4-dNSCLC.

关 键 词：SWI/SNF复合体 SMARCA4 BRG1 非小细胞肺癌 治疗 

分 类 号：R734.2[医药卫生—肿瘤]